Table 2:

Univariate and multivariate analyses of MATS and clinicopathological parameters in the in-house training and validation cohorts

	Training Cohort (N=142)				Validation Cohort (N=286)
	Univariate		Multivariate		Univariate		Multivariate
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
Age (≥65)	1.39 (0.67–2.87)	0.37			1.22 (0.77–1.94)	0.39
Gender (M vs. F)	2.41 (1.04–5.60)	0.04	1.81 (0.74–4.39)	0.19	1.00 (0.65–1.54)	1
Location (Rectum)	1.64 (0.79–3.40)	0.18			1.93 (1.25–2.97)	0.002	1.66 (1.04–2.65)	0.03
Differentiation	1.16 (0.35–3.80)	0.81			0.95 (0.44–2.06)	0.91
T4 vs. T2&3	2.91 (1.43–5.95)	0.003	2.10 (1.00–4.40)	0.04	1.90 (1.23–2.94)	0.004	1.71 (1.07–2.75)	0.02
Venous Invasion	2.10 (0.91–4.88)	0.08			2.31 (0.85–6.27)	0.1
Lymphatic Invasion	2.31 (1.13–4.73)	0.02	1.68 (0.80–3.52)	0.17	1.90 (1.20–3.01)	0.006	1.27 (0.75–2.16)	0.37
Lymphnode metastasis	2.37 (1.02–5.52)	0.04	2.25 (0.94–5.40)	0.06	2.49 (1.59–3.90)	0.0001	1.64 (0.99–2.73)	0.05
Examined LN Number (<12)	1.09 (0.34–3.60)	0.88			1.28 (0.74–2.20)	0.38
CEA (≥5)	0.92 (0.42–2.01)	0.84			1.82 (1.17–2.81)	0.007	1.79 (1.14–2.81)	0.01
MSI					4.20 (1.04–16.9)	0.04	3.16 (0.76–13.9)	0.11
MATS	4.11 (2.02–8.42)	0.0001	3.75 (1.78–7.89)	0.0005	2.10 (1.28–3.44)	0.0001	2.10 (1.28–3.44)	0.003